FBLG vs. ORGO, AMRN, PGEN, VRCA, ANRO, SKYE, NBTX, VTYX, ACIU, and TERN
Should you be buying FibroBiologics stock or one of its competitors? The main competitors of FibroBiologics include Organogenesis (ORGO), Amarin (AMRN), Precigen (PGEN), Verrica Pharmaceuticals (VRCA), Alto Neuroscience (ANRO), Skye Bioscience (SKYE), Nanobiotix (NBTX), Ventyx Biosciences (VTYX), AC Immune (ACIU), and Terns Pharmaceuticals (TERN). These companies are all part of the "pharmaceutical preparations" industry.
Organogenesis (NASDAQ:ORGO) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership, community ranking and profitability.
In the previous week, Organogenesis had 1 more articles in the media than FibroBiologics. MarketBeat recorded 3 mentions for Organogenesis and 2 mentions for FibroBiologics. Organogenesis' average media sentiment score of 1.42 beat FibroBiologics' score of 0.91 indicating that FibroBiologics is being referred to more favorably in the news media.
Organogenesis received 96 more outperform votes than FibroBiologics when rated by MarketBeat users.
49.6% of Organogenesis shares are held by institutional investors. 34.0% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Organogenesis has higher revenue and earnings than FibroBiologics.
Organogenesis has a net margin of 1.34% compared to Organogenesis' net margin of 0.00%. FibroBiologics' return on equity of 2.11% beat Organogenesis' return on equity.
Organogenesis presently has a consensus price target of $4.83, suggesting a potential upside of 81.02%. Given FibroBiologics' higher probable upside, equities analysts clearly believe Organogenesis is more favorable than FibroBiologics.
Summary
Organogenesis beats FibroBiologics on 11 of the 12 factors compared between the two stocks.
Get FibroBiologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBLG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
FibroBiologics Competitors List
Related Companies and Tools
